Mon, September 27, 2010
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ]: Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ]: Market Wire
Transdel Pharmaceuticals

Micromet to Present at the 2010 UBS Global Life Sciences Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. he-2010-ubs-global-life-sciences-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

BETHESDA, Md.--([ BUSINESS WIRE ])--Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 UBS Global Life Sciences Conference, to be held September 20 - 22, 2010 in New York City. Christian Itin, Ph.D., Micrometa™s President and Chief Executive Officer, will present a 30 minute corporate overview on September 20 at 11:30 AM ET.

The presentation will be webcast live and may be accessed by visiting the Micromet website at [ www.micromet.com ]. A replay of the webcast will also be available on the Company's website.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at [ www.micromet.com ].


Publication Contributing Sources